Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
A phase 3 trial of Bicalutamide, Flutamide, Goserelin / leuprolide, Buserelin, Triptorelin and Degarelix in Prostate cancer, run by Radiation Therapy Oncology Group, completed.
Overview
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer is a phase 3 interventional study registered as NCT00936390 by Radiation Therapy Oncology Group, with 1538 participants recorded, started 2009-09 and reaching its primary completion in 2020-10-03. Interventions recorded: bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy. Conditions recorded: Prostate Cancer.
Linked to the drug Buserelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialProstate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Shares Buserelin, Flutamide, Triptorelin, Bicalutamide and the tag pipeline.
- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Buserelin, Flutamide, Degarelix, Triptorelin and the tag pipeline.
- TrialHormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialHormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Flutamide, Degarelix, Triptorelin, Bicalutamide and the tag pipeline.
- TrialNeoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialInvestigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialTriptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
Shares Flutamide, Triptorelin, Prostate cancer and the tag pipeline.